However, groups 1 and 3 both contain a number of virtual patients with tumor characteristics that are associated with poor response to BMP4, therefore diluting the overall observed benefit of BMP4, resulting in many fewer trials identifying BMP4 as a potential treatment. Here, BMP4 is linked to neoplasm.